Your browser does not support JavaScript! Turn on JavaScript support in your browser.
:::
 
Symptom
IRB NO.
Clinical trial title
Principal Investigator
Department
Assistant Phone
Femtosecond Ophthalmic
N202005019
Intracorneal Lenticular Extraction refractive surgery with Femtosecond Ophthalmic laser Femton F1
Chien-Liang
Wu
Ophthalmology
Hsiu-Yen
Wang
0229307930#2543
Femtosecond Ophthalmic
N202005020
Femtosecond FLEX Application with
Chien-Liang
Wu
Ophthalmology
Hsiu-Yen
Wang
0229307930#2543
Lung Cancer
N202107070
A Prospective, Randomized, Open-Label, Add-On, Parallel Control Study to Investigate Safety and Efficacy of the cold water extract of Arthrospira maxima in Patients with Ambulatory Mild and Moderated Disease COVID-19
Fu-Lun Chen
Infection
Hsiu-Yen
Wang
0229307930#2543
COVID-19
N202306066
A Randomized, Double blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting
Chia-Lun Chang
Hematology
and Oncology
Wei-Ling
Zhou
0914019869
Cell Therapy
N202305080
ARTEMIS: Ravulizumab To Protect Patients With Chronic Kidney Disease (CKD) From Cardiac Surgery Associated Acute Kidney Injury (CSA AKI) And Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Chun-Che Shih
Cardiovascular Surgery
Sih-Chen
Wang
0958131385
Tibial fracture
N202301037
A Phase I, Open-label, Dose-escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Modified Salmonella Typhimurium SGN1 Administered via Intratumoral Injection in Patients with Advanced Solid Tumors
Chia-Lun Chang
Hematology and Oncology
Wei-Ling
Zhou
0914019869
Chronic Kidney Disease
N202206025
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Jia-Ying Sung
Neurology
Hsiu-Chen
Chang
0229307930#2550
Hypertension
N202204010
A randomized, evaluator-blinded, controlled study to evaluate the safety and clinical performance of OIF/β-TCP in patients with open tibial fractures in need of bone grafting.
Yi-Jie
Kuo
Orthopedics
Hsiu-Chen
Chang
0229307930#2550
Pancreatic Cancer
N202108058
Develop the umbilical cord mesenchymal stem cell model from human umbilical cord
Le-Ming Wang
Obstetrics/
Gynecology
Yi-Jie
Ding
02-89797888#118
Acute Respiratory Syncytial Virus Infection
N202207016
A Multicentre, Randomized, Double-blind Study to Evaluate and Compare the Efficacy and Safety of 8-week Treatment with Azilsartan Medoxomil and Amlodipine Besylate Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects
Ming-Hsiung Hsieh
Cardiology
Sih-Chen
Wang
0958131385
Solid tumors
N202208004
A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
Tzeon-Jye Chiou
Hematology and Oncology
Sih-Chen
Wang
0958131385
Viral Lung Infection Requiring Supplemental Oxygen
N202005024
Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation
Chia-Lun Chang
Hematology and Oncology
Wei-Ling
Yang
0229307930#2556
Chronic Kidney Disease
N202302038
A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA)
Tsong-Yih Ou
Infection
Hsiu-Chen
Chang
0229307930#2550
Melanoma
N202301029
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of EDP-938 in Non-hospitalized Adults with Acute Respiratory Syncytial Virus Infection who are at High Risk for Complications
Tsong-Yih Ou
Infection
Hsiu-Chen
Chang
0229307930#2550